<DOC>
	<DOCNO>NCT02434263</DOCNO>
	<brief_summary>The purpose study evaluation performance , safety efficacy Hydra Aortic valve real-world patient . Following initial implantation , patient clinical follow 30 day , 3 , month , 6 month 12 month</brief_summary>
	<brief_title>A Clinical Evaluation HYDRA Self Expanding Transcatheter Aortic Valve</brief_title>
	<detailed_description>This study multicenter , prospective , non-randomized investigational study design assess safety performance HYDRA Aortic valve delivery system . Primary endpoint safety 30 day cause mortality rate . Primary endpoint performance acute device success . In addition , efficacy HYDRA Aortic valve delivery system evaluate . Approximately 70 patient enrol study order achieve 60 subject successfully implant . All patient clinical follow-up 30 day , 3months , 6 month 12 month post implant . The follow-up procedure table show Appendix A . The patient enrol study subject upon signature inform consent . All subject review Principal Investigator prior undergo implant procedure Hydra Aortic Heart Valve .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Aortic annulus diameter meet range 18 28mm measure CT conduct within past 120 day , echocardiogram ( TEE 3D recommend ) medically contraindicate CT. 2 . Patient severe degenerative aortic stenosis echocardiography derive mean gradient &gt; 40mmHg and/or peak velocity great 4.0 m/s and/or initial valve area &lt; 1.0 cm2 . 3 . Patient symptomatic aortic stenosis demonstrate NYHA Functional Classification II great . 4 . Patient deem high operable risk suitable TAVI . 5 . Patient 's predicted operative mortality serious , irreversible morbidity risk &lt; 50 % 30 day . 6 . Patient structurally normal cardiac anatomy . 7 . Willing able comply require followup evaluation 1 . Patient history cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month . 2 . Patient carotid artery disease require intervention . 3 . Patient evidence myocardial infarction ( MI ) within past 6 month . 4 . Patient hypertrophic cardiomyopathy . 5 . Patient native aortic valve congenitally unicuspid , bicuspid , quadricuspid noncalcified see echocardiography . 6 . Patient mitral tricuspid valvular regurgitation ( &gt; grade III ) moderate severe mitral stenosis . 7 . Patient aortic root angulation &gt; 70 degree ( horizontal aorta ) . 8 . Patient aortic root diameter &lt; 26 mm &gt; 36 mm . 9 . Patient preexist prosthetic valve prosthetic ring position . 10 . Patient refuse blood transfusion surgical valve replacement . 11 . Patient rest leave ventricular ejection fraction ( LVEF ) &lt; 20 % . 12 . Patient document , untreated symptomatic coronary artery disease ( CAD ) require revascularization . 13 . Patient severe basal septal hypertrophy . 14 . Patient percutaneous interventional invasive cardiac peripheral procedure ≤ 14 day index procedure ( apply diagnostic angiography AngioCT ) . 15 . Patient history active endocarditis . 16 . Patient echocardiographic evidence intracardiac mass , thrombus , vegetation . 17 . Patient hemodynamic instability ( require inotropic support mechanical heart assistance ) . 18 . Patient acute pulmonary edema require intravenous diuretic therapy stabilize heart failure . 19 . Patient significant pulmonary disease ( FEV1 &lt; 30 % predict ) . 20 . Patient significant chronic steroid use determine documented Principle Investigator . 21 . Patient known hypersensitivity contraindication anticoagulant antiplatelet medication . 22 . Patient renal insufficiency evidence serum creatinine &gt; 3.0 mg/dL ( 265.5μmol/L ) endstage renal disease require chronic dialysis . 23 . Patient 's iliofemoral artery severe calcification , tortuosity ( &gt; two 90 degree bend ) , diameter &lt; 6mm , subject aortafemoral bypass preclude safe placement 18 French sheath . 24 . Patient blood dyscrasia ( leukopenia , acute anemia , thrombocytopenia , bleed diathesis , coagulopathy ) . 25 . Patient current autoimmune disease , opinion Principal Investigator precludes subject study participation . 26 . Patient significant aortic disease . 27 . Patient preexist endovascular stent graft supra infrarenal aorta preexist stent graft iliofemoral artery . 28 . Patient active peptic ulcer gastrointestinal ( GI ) bleed within past 90 day prior procedure 29 . Patient life expectancy &lt; 12 month . 30 . Patient medical , social psychological condition , opinion Principal Investigator , preclude subject study participation . 31 . Patient know allergy contrast medium , nitinol alloy bovine tissue . 32 . Patient history cognitive mental health status would interfere study participation . 33 . Currently participate another trial .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>